These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
96 related articles for article (PubMed ID: 2675003)
21. [Cytokine therapy of superficial bladder carcinoma. Mechanisms of action and results of therapy]. Otto T; Kälble T Urologe A; 1994 Nov; 33(6):540-6. PubMed ID: 7817454 [TBL] [Abstract][Full Text] [Related]
24. [Severe self-limiting hypersensitivity reaction after immunotherapy with intravesical BCG]. Estelles Piera FJ; Campayo A; Valls Ferrer JM; Lacruz J; Blanes Julia FM; López Aldeguer J; Bonora Tamarit V An Med Interna; 1994 Oct; 11(10):503-5. PubMed ID: 7865660 [TBL] [Abstract][Full Text] [Related]
25. Serial urinary IL-2, IL-6, IL-8, TNFalpha, UBC, CYFRA 21-1 and NMP22 during follow-up of patients with bladder cancer receiving intravesical BCG. Sanchez-Carbayo M; Urrutia M; Romani R; Herrero M; Gonzalez de Buitrago JM; Navajo JA Anticancer Res; 2001; 21(4B):3041-7. PubMed ID: 11712808 [TBL] [Abstract][Full Text] [Related]
26. [Treatment and follow-up of superficial bladder cancer]. Raitanen M Duodecim; 2002; 118(9):903-9. PubMed ID: 12238168 [No Abstract] [Full Text] [Related]
27. In situ transitional cell carcinoma involvement of prostatic urethra: bacillus Calmette-Guérin therapy without previous transurethral resection of the prostate. Palou J; Xavier B; Laguna P; Montlleó M; Vicente J Urology; 1996 Apr; 47(4):482-4. PubMed ID: 8638354 [TBL] [Abstract][Full Text] [Related]
28. [The immunotherapy and immunoprophylaxis of bladder cancer]. Figurin KM; Tsiganu VI Urol Nefrol (Mosk); 1993; (4):46-9. PubMed ID: 8310570 [No Abstract] [Full Text] [Related]
29. BCG-RIVM intravesical immunoprophylaxis for superficial bladder cancer. Debruyne FM; van der Meijden AP; Schreinemachers LM; Geboers AD; Franssen MP; van Leeuwen MJ; Steerenberg PA; de Jong WH; Ruitenberg EJ Prog Clin Biol Res; 1988; 269():511-24. PubMed ID: 3134662 [No Abstract] [Full Text] [Related]